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Summary The efficacy of high-dose chemotherapy (HDC) and circulating progenitor cell (CPC) transplantation in metastatic breast cancer
(MBC) relies mainly on giving this treatment after a response to conventional induction chemotherapy has been achieved. For this reason an
optimal mobilization regimen should be therapeutically effective while minimizing the number of leucaphereses required to support the
myeloablative therapy. The combination of an anthracycline and paclitaxel in chemotherapy-untreated MBC has produced impressive
response rates. We evaluated the CPC-mobilizing capacity of the combination epirubicin (90 mg m-2) and paclitaxel (135 mg m-2) followed by
filgrastim (5 Ag kg-1 day-1) starting 48 h after chemotherapy administration in ten patients with MBC who were eligible for an HDC and CPC
transplantation programme. Leucaphereses were performed by processing at least two blood volumes per procedure at recovery from
neutrophil nadir when CD34+ cells in the peripheral blood exceeded 20 [I-. In most patients (six out of 10) more than 2.5 x 106 CD34+ cells
kg-', a threshold considered to be sufficient for haematopoietic reconstitution, were collected with a single apheresis. In the remaining four
patients an additional procedure, performed the following day, was enough to reach the required number of progenitors. These data suggest
that the epirubicin-paclitaxel combination, besides being a very active regimen in MBC, is effective in releasing large amounts of progenitor
cells into circulation.
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The autologous transfusion of circulating progenitor cells (CPCs)
collected from the peripheral blood by leucapheresis is rapidly
replacing autologous bone marrow transplantation to support
haematopoiesis after high-dose chemotherapy (HDC) for
lymphoma and solid tumours (Gianni AM, 1994; Holoyake,
1994). The main reason for the success of this procedure is the
capability of CPCs to produce a much faster haematopoietic
recovery than bone marrow cells (Siena et al, 1989; Sheridan et al,
1992; Chao et al, 1993; Schmitz et al, 1996).
An adequate number ofprogenitor cells capable ofguaranteeing
short- and long-term haematopoiesis can be harvested from the
peripheral blood after treatment with haematopoietic growth
factors administered as single agents or, more frequently, following
myelosuppressive chemotherapy (Bensinger et al, 1993; Siena et
al, 1994). Moreover, mobilization with disease-oriented chemo-
therapy in addition to cytokines is particularly recommended in
patients with chemosensitive neoplasms as the greater efficacy of
mobilization is combined with the anti-tumour effect of the drug.
In fact, in most CPC transplantation programmes the mobilizing
regimens include agents (often at high doses) with proven efficacy
against the underlying disease (Brugger et al, 1992; Shimazaki et
al, 1992; Gianni AM et al, 1995).
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Controversy still surrounds the use ofHDC with CPC support in
stage IV breast cancer (Shpall et al, 1994; Hortobagyi, 1995;
Kennedy, 1995), mainly because of a lack of large randomized
trials. However, a number of phase II studies (Peters et al, 1988;
Antman et al, 1992) and two recent phase III studies (Bezwoda et
al, 1995; Peters et al, 1996) have shown that this approach may
result in an increase in disease-free survival and overall survival
and may be curative in a small subset ofpatients. In addition, there
is strong evidence that the efficacy of HDC in MBC is mainly
dependent on the possibility oftreating women who have shown a
response to conventional chemotherapy regimens (Antman et al,
1992; Shpall et al, 1994). In this scenario, an ideal first-line
regimen for patients with stage IV breast cancer should have, first,
the ability to induce high response rates and, second, the capacity
to mobilize sufficient numbers ofhaematopoietic progenitors. It is
already known that the combination of an antracycline and pacli-
taxel meets the first requirement. In fact, despite the involvement
of taxanes and anthracyclines in the multiple drug resistance
phenotype (Podda et al, 1992), paclitaxel induced objective
responses in 20-40% of patients who failed to respond to prior
treatment with anthracyclines (Gianni L et al, 1995a; Seidman et
al, 1995), and the combination of the two resulted in impressive
response rates in previously untreated women (Hortobagyi et al,
1994; Gianni L et al, 1995b; Sledge et al, 1995).
In the present study, ten patients with MBC were given the
anthracycline epirubicin and paclitaxel to achieve cytoreduction
before transplantation and to facilitate CPC collection.
Data onprogenitor cell harvesting and preliminary response rate
are reported.
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Table 1 Patient characteristics
Number
Median age (range)
Metastatic sites
Skin/soft tissue
Nodes
Liver
Lung
Bone
Other
> 1 metastatic site
Previous adjuvant therapy
CMF
EPI/CMF
Tamoxifen
Radiotherapy
Disease-free interval (months)
10
49 (33-59)
4
4
3
3
2
2
7
5
3
7
5
22 (6-104)
CMF, cyclophosphamide, methotrexate, 5-fluorouracil; EPI/CMF,
epirubicin/CMF.
PATIENTS AND METHODS
Patients
Ten women with stage IV breast cancer entered the study after
giving written informed consent. The main patient characteristics
are listed in Table 1. No patient received prior treatment for
advanced disease and none had histological evidence ofneoplastic
bone marrow involvement or hypocellular marrow at the time of
chemotherapy administration.
Treatment
Patients received epirubicin 90 mg m-2 by i.v. bolus injection
followed by paclitaxel 135 mg m-2 by 3-h i.v. infusion. Pre-
medication to prevent paclitaxel-induced hypersensitivity reac-
tions included steroids, chlorpheniramine and ranitidine. Doses
and administration schedules of chemotherapeutic agents were
based on previously reported studies (Buzdar et al, 1995; Gianni L
et al, 1995b) and on our own preliminary experience. Epirubicin
was used instead of doxorubicin because it has the same anti-
tumour effect and lower cardiotoxicity (Bonadonna et al, 1993).
Filgrastim was given s.c. at a dose of 5 ,tg kg-' daily starting 48 h
after chemotherapy administration. Patients continued to receive
filgrastim through the final day of leucapheresis. Ciprofloxacin
500 mg orally twice per day was given when the WBC count
dropped below 1.5 x 1091-'. Toxicity and response were assessed
according to World Health Organization guidelines (WHO, 1979).
All patients were programmed to receive at least three cycles of
chemotherapy before response was evaluated. Complete respon-
ders were given HDC with stem cell support, whereas patients
with partial response (PR) or stable disease received three more
cycles of the epirubicin-paclitaxel combination. If progression
was documented, a second-line treatment was given.
CPC collection
CPCs were collected after the first chemotherapy cycle in eight
patients and after the second in two. Leucaphereses were performed
with a continuous blood cell separator Cobe Spectra, and a
minimum of two blood volumes per procedure were processed as
described previously (Torretta et al, 1996). Blood flow rate was
40-50 ml min-' and the ACD-whole blood ratio was 1:11. We
routinely administered 10% calcium gluconate in continuous infus-
ion (3.3 mmol [-1) to prevent hypocalcaemia symptoms. Collection
was planned so as toobtain aproduct with afinal haematocritof4%.
Leucaphereses were performed upon recovery from neutrophil
nadir when circulating CD34+ cells exceeded 20 p3-'. The trigger
value of 20 CD34+ cells itl-l was chosen on the basis of previous
reports (Siena et al, 1991; Zimmerman et al, 1995).
Our final target for collection was a minimum of 2.5 x 106
CD34+ cells kg-' body weight. If the CD34+ cells harvested with
the first collection were fewer than that amount, an additional
procedure was performed the following day. When the study was
designed very few data were available concerning the mobilization
capacity of the epirubicin-paclitaxel combination and the
threshold of CD34+ cell harvest was chosen based on previous
reports (Bender et al, 1992; Bensinger et al, 1995) and our own
experience.
Table 2 Summary of results obtained in the study
PHN Apheresis Day WBC x 1091-' CD34+ Total CAFCs CD34+
of collection at collection [L1P PB x 106 x 106 kg-'
5020 1 +11 9.6 39 ND 1.9
2 +12 16.0 32 ND 2.6
5037 1 +12 6.1 49 ND 2.8
4992 1 +13 15.2 58 2.7 5.2
5131 1 +11 6.7 44 0.7 1.9
2 +12 17.0 70 3.1 5.3
4990 1 +8 5.4 43 3.0 2.2
2 +9 17.1 96 ND 7.8
4994 1 +12 16.0 24 2.4 3.1
5011 1 +11 24.8 55 3.7 4.0
4981 1 +10 15.7 131 4.9 5.2
5108 1 +10 7.1 21 1.5 1.2
2 +11 12.1 30 2.7 2.3
4756 1 +10 13.5 52 3.1 4.2
10 14 +11 14.3 48.5 3.0 2.8
(+8 to +13) (5.4-24.8) (21-131) (0.7-4.9) (1.2-7.8)
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Figure 1 Timing of the 14 leucapheresis procedures after epirubicin-
paclitaxel chemotherapy. CPC harvesting was performed in the presence of
at least 20 circulating CD34+ cells zI-'
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Figure 2 Contribution of the first (U) and second (U) leucapheresis
procedures to the total amount of CD34+ cells collected in ten patients after
the epirubicin-paclitaxel regimen
Flow cytometry
Expression ofthe surface membrane CD34 antigen was evaluated
as described previously (Siena et al, 1991). Briefly, 50 tl ofwhole
blood regardless ofcell count was incubated at 220C for 30 min in
PBS-1% BSA with a phycoerythrin (PE)-conjugated anti-CD34
MAb (HPCA-2, clone 8G12, Becton Dickinson, Mountain View,
CA, USA). By means of flow cytometry (FACScan, Becton
Dickinson), the percentage of stained cells was determined from
comparison with PE-conjugated mouse isotypic control. Cell
viability was evaluated by staining with ethidium bromide and
acridine orange. Dead cells were gated out as orange fluorescence.
Evaluation of cobblestone area forming cells (CAFCs)
The extent of CAFC mobilization was evaluated following the
limiting dilution analysis (LDA) assay described by Pettengell et
al (1994), using low-density cells (LDCs) separated over
Ficoll-Hypaque (1077 g ml-; Cedar Lane, Hornby, Ontario,
Canada). Briefly, 9000 genetically engineered M2-10B4 murine
stromal cells were plated, after 80 Gy irradiation, in 96-well
microtitre flat-bottomed plates. Cultures were scaled down to
200 1t of long term myelocult medium (Stem Cell Technologies,
Vancouver, Canada) and performed at limiting dilution using ten
replicates per dilution step. A minimum of 100 and maximum of
15 000 cells per well were seeded and cultures were fed weekly.
After 5 weeks, wells were evaluated as positive or negative for
the presence of cobblestone areas, defined as clusters of small,
tightly packed cells that were non-refractory when viewed under a
phase-contrast microscope and originated from a CAFC. Wells
with cobblestone areas greater than 15 cells or three separate foci
ofmore than five cells were scored as positive.
Data analysis
Statistical comparisons were performed with Primer (McGraw-
Hill, New York, NY, USA) and Statview (Abacus Concepts,
Berkley, CA, USA) software, and the Mann-Whitney, Wilcoxon
and Kruskal-Wallis tests were used for non-parametric analyses.
Estimates of CAFC proportions were analysed by standard LDA
(Pettengell et al, 1994). Values of P lower than 0.05 were consid-
ered statistically significant.
RESULTS
Chemotherapy toxicity
The median nadir of WBC and platelet counts occurred on days 7
(range 6-9) and 8 (range 6-10) respectively. Median neutrophil
count at nadir was 0.49 x 1091-1 (range 0.175-1.68). No patient's
platelet count dropped below 50 x 109 1-1 (median 87, range
58-209). Two patients developed grade 2 neutropenic feverbut no
infections were documented. One patient experienced grade 1
neurological and two grade 1 gastrointestinal toxicity. There were
no hypersensitivity or cardiovascular complications. Patients were
hospitalized only for chemotherapy administration.
CPC harvesting
Fourteen leucaphereses were performed in our ten patients. In four
out of ten cases the number of CD34+ cells collected the first day
was below our target (median 1.9 x 106 kg-1 body weight, range
1.2-2.2) and an additional procedure had to be performed. Median
WBC and circulating CD34+ counts on the first day of collection
were 11.5 x 103 lI-p (range 5.4-24.8) and 48 pl-1 (range 21-131)
respectively (Table 2). As a consequence of the variability in
peripheral blood WBC counts, the total number of WBCs
collected varied from procedure to procedure (median 28.5 x 109
range 8-63). The median time ofCPC collection was the 11th day
after paclitaxel-epirubicin administration (range 8-13). Most of
the procedures were carried out on day 10 to day 12 (Figure 1).
In all cases the target of 2.5 x 106 kg-1 CD34+ cells kg-1 was
reached. The median numbers of CD34+ cells collected per leuca-
pheresis and per patient were 2.8 (range 1.2-7.8) and 4.35
(2.8-10) respectively (Figure 2).
Finally, the median number of CAFCs per leucapheresis was
3.0 x 106 (range 0.7-4.9).
Treatment response and CPC transplantation
Three patients achieved complete response (CR), four reached PR
and three showed no response or progressive disease after three
cycles of the epirubicin-paclitaxel combination. One PR patient
obtained CR after three additional cycles ofchemotherapy.
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So far, four ofthese patients have undergone HDC and stem cell
support. All ofthem received the same preparative regimen, which
included thiotepa, carboplatin and cyclophosphamide (Antman et
al, 1992). The median days needed to reach an absolute neutrophil
count of > 0.5 x 109 1-' and a platelet count of 20 x 109 1-' were 9
and 10, respectively, after infusion of peripheral blood progenitor
cells. No graft failure was observed at a median follow-up of
8.5 months (range 5-14).
DISCUSSION
Autologous CPCs are increasingly being used as a source of
haematopoietic stem cells following HDC for solid tumours
because of their ease of collection and the faster neutrophil and
platelet recovery as compared with marrow (Siena et al, 1994).
Besides, CPCs are less likely to be contaminated by tumour cells
capable ofclonogenic growth in vitro (Ross et al, 1993).
A variable number of leucaphereses are needed to harvest the
optimal dose of CPCs. Collection after chemotherapy, either at
conventional or high doses, followed by haematopoietic growth
factor(s) administration takes advantage of the additional mobil-
izing effect of the myelotoxic drugs. As a consequence, the yield
of the collection is more predictable and fewer leucapheresis
procedures are needed.
Limited preliminary data are available regarding the use of
paclitaxel alone or in combination with other agents in facilitating
CPC collection. Recently, Demirer et al (1995) have shown that
paclitaxel and cyclophosphamide followed by filgrastim mobilize
CPC in patients with advanced ovarian and breast cancer more
effectively than cyclophosphamide alone. Other authors have also
reported successful stem cell harvesting after paclitaxel adminis-
tration (Fennelly et al, 1995).
Mobilizing cytotoxic agent(s) must be chosen from among
those with proven activity against the underlying disease. This is
especially important in those conditions, e.g. advanced breast
cancer, in which transplantation is performed mainly in patients
who have shown optimal response to first-line induction
chemotherapy.
Despite the controversy over the number of autologous CPCs
required to support myeloablative regimens, an amount greater
than 2.5 x 106kg-' body weight CD34+ cells is considered by many
authors to be sufficient for a safe haematopoietic reconstitution
(Bender et al, 1992; Bensinger et al, 1995; Schwella et al, 1996).
The tempo ofplatelet engraftment has been reported to be delayed
in some patients when less than 5 x 106 CD34+ cells kg-' body
weight are reinfused (Bensinger et al, 1995). However, small
differences between studies and groups of patients may reflect the
difficulties in standardizing the quantitative assay used as well as
being due to biological reasons related to previous exposure to
chemotherapy (Tricot et al, 1995).
In the present study, after the administration ofepirubicin, pacli-
taxel and filgrastim, most patients reached the target of 2.5 x 106
kg-' CD34+ cells with a single leucapheresis. Interestingly, when a
second harvest had to be performed, the total number of CD34+
cells was higher than that collected at the first procedure (P <
0.001).
Overall, our data suggest that a trigger value of45 CD34+ cells
tl-' in circulation indicates the best day for the apheresis proce-
dure. In fact, five out of five patients who presented more than 45
CD34+ cells l-' collected > 2.5 x 106 CD34+ cells kg-', whereas
four out of five patients with fewer than 45 CD34+ cells il-' failed
to harvest an adequate amount of progenitors at the first leuca-
pheresis procedure. In an attempt to make a single leucapheresis
feasible in all patients, further optimization ofharvesting timing is
now under investigation on a larger number of subjects.
As a contribution towards identifying the total number of
CAFCs needed for safe and rapid haematopoietic reconstitution,
we used LDA to calculate the CAFC (or long-term culture-
initiating cell, LTC-IC) in leucapheresis. This is currently thought
to be the best surrogate for early progenitor cell enumeration
(Hows et al, 1992; Pettengell et al, 1994; Ploemacher, 1994), and
in a recent clinical study (Breems et al, 1996) a reduction of
engraftment potential in CAFC-poor leucapheresis has been
demonstrated. In relation to this, we are currently evaluating the
correlation between the total number of CAFCs collected after
various mobilization regimens and their short- and long-term
engraftment potential.
In conclusion, the epirubicin-paclitaxel combination followed
by filgrastim is effective in releasing large numbers of progenitor
cells into the peripheral blood of patients with advanced breast
cancer. Given its high therapeutic efficacy and limited toxicity we
believe that this combination should be employed as induction
therapy before high-dose regimens in selected patients with stage
IV disease.
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